Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation

References

• Hartman M Martin A McDonnell P Catlin A National Health Expenditure Accounts Team National health spending in 2007: slower drug spending contributes to lowest rate of overall growth since 1998 Health Aff (Millwood) 2009 28 1 246 261 19124877
   PubMed Web of Science ®Google Scholar
• Hotta K Matsuo K Ueoka H Kiura K Tabata M Tanimoto M Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer J Clin Oncol 2004 22 19 3852 3859 15326195
   PubMed Web of Science ®Google Scholar
• Hotta K Matsuo K Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small cell lung cancer J Thorac Oncol 2007 2 1 96 17410021
   PubMed Web of Science ®Google Scholar
• Hamdi T Latta S Jallad B Kheir F Alhosaini MN Patel A Cisplatin-induced renal salt wasting syndrome South Med J 2010 103 8 793 799 20622742
   PubMed Web of Science ®Google Scholar
• Raftopoulos H Diagnosis and management of hyponatremia in cancer patients Support Care Cancer 2007 15 12 1341 1347 17701059
   PubMed Web of Science ®Google Scholar
• Sekine I Kubota K Tamura Y Innovator and generic cisplatin formulations: comparison of renal toxicity Cancer Sci 2011 102 1 162 165 21054679
   PubMed Web of Science ®Google Scholar
• Niho S Yamanaka T Umemura S Renal toxicity caused by brand-name versus generic cisplatin: a comparative analysis Jpn J Clin Oncol 2013 43 4 390 395 23444114
   PubMed Web of Science ®Google Scholar
• Hotta K Takigawa N Hisamoto-Sato A Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002 Jpn J Clin Oncol 2013 43 11 1115 1123 24082005
   PubMed Web of Science ®Google Scholar
• Kefalas CH Ciociola AA The FDA’s generic-drug approval process: similarities to and differences from brand-name drugs Am J Gastroenterol 2011 106 6 1018 1021 21637264
   PubMed Web of Science ®Google Scholar
• van der Meersch A Dechartres A Ravaud P Quality of reporting of bioequivalence trials comparing generic to brand name drugs: a methodological systematic review PLoS One 2011 6 8 e23611 21858184
   PubMed Web of Science ®Google Scholar
• Kesselheim AS Misono AS Lee JL Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis JAMA 2008 300 21 2514 2526 19050195
   PubMed Web of Science ®Google Scholar
• Dentali F Donadini MP Clark N Warfarin Associated Research Projects and Other Endeavors (WARPED) Consortium Brand name versus generic warfarin: a systematic review of the literature Pharmacotherapy 2011 31 4 386 393 21449627
   PubMed Web of Science ®Google Scholar
• Caldeira D Fernandes RM Costa J David C Sampaio C Ferreira JJ Branded versus generic clopidogrel in cardiovascular diseases: a systematic review J Cardiovasc Pharmacol 2013 61 4 277 282 23188124
   PubMed Web of Science ®Google Scholar
• Kesselheim AS Stedman MR Bubrick EJ Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis Drugs 2010 70 5 605 621 20329806
   PubMed Web of Science ®Google Scholar
• Yamada M Welty TE Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies Ann Pharmacother 2011 45 11 1406 1415 22028417
   PubMed Web of Science ®Google Scholar
• Emanuele E Generic versus brand name drugs in psychopharmacology: a pharmacoeconomic perspective South Med J 2011 104 10 715 716 21941163
   PubMed Web of Science ®Google Scholar
• Talati R Scholle JM Phung OP Efficacy and safety of innovator versus generic drugs in patients with epilepsy: a systematic review Pharmacotherapy 2012 32 4 314 322 22461121
   PubMed Web of Science ®Google Scholar
• Dong BJ Hauck WW Gambertoglio JG Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism JAMA 1997 277 15 1205 1213 9103344
   PubMed Web of Science ®Google Scholar
• Kim SH Park K Hong SJ Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial Clin Ther 2010 32 11 1896 1905 21095484
   PubMed Web of Science ®Google Scholar
• Carswell JM Gordon JH Popovsky E Hale A Brown RS Generic and brand-name L-thyroxine are not bioequivalent for children with severe congenital hypothyroidism J Clin Endocrinol Metab 2013 98 2 610 617 23264396
   PubMed Web of Science ®Google Scholar
• Olufolabi AJ Gan TJ Lacassie HJ White WD Habib AS A randomized, prospective double-blind comparison of the efficacy of generic propofol (sulphite additive) with diprivan Eur J Anaesthesiol 2006 23 4 341 345 16438763
   PubMed Web of Science ®Google Scholar
• Vial J Cohen M Sassiat P Thiébaut D Pharmaceutical quality of docetaxel generics versus originator drug product: a comparative analysis Curr Med Res Opin 2008 24 7 2019 2033 18544188
   PubMed Web of Science ®Google Scholar
• Leelarasamee A Rongrungruang Y Trakulsomboon S Pongpech P Thanawattanawanich P Jithavech P Bioequivalence, antibacterial activity and therapeutic outcome of a generic meropenem (Mapenem) J Med Assoc Thai 2008 91 7 980 988 18839835
   PubMedGoogle Scholar
• Thamlikitkul V Tiengrim S Chalermsri C Chinsawangwatanakul P Suddhichupaiboon S Microbiological equivalence of serum bacteriostatic and bactericidal activities of the sera from healthy volunteers receiving original meropenem (Meronem) and generic meropenem (Mero) J Med Assoc Thai 2010 93 Suppl 1 S110 S116 20364565
   PubMedGoogle Scholar
• Nakamura I Ichimura E Kobayashi H Comparative study of peripheral neurotoxicity after injection of two different paclitaxel formulations in rats Arzneimittelforschung 2010 60 4 205 209 20486471
   PubMed Web of Science ®Google Scholar
• Thamlikitkul V Tiengrim S Chalermsri C Sae-Jong R Suddhichupaiboon S Microbiological equivalence of bacteriostatic and bactericidal activities of the sera from healthy volunteers receiving generic piperacillin/tazobactam (Pipertaz) and original piperacillin/tazobactam (Tazocin) J Med Assoc Thai 2011 94 Suppl 1 S196 S202 21721447
   PubMedGoogle Scholar
• Oike T Ohno T Noda SE Comparison of hematological toxicities between innovator and generic cisplatin formulations in cervical cancer patients treated with concurrent chemoradiotherapy J Radiat Res 2013 54 3 474 478 23242248
   PubMed Web of Science ®Google Scholar
• Tsukiyama I Hotta K Takeuchi M Evaluation of safety in clinical use of generic paclitaxel [NK] for injection Gan To Kagaku Ryoho 2012 39 4 613 617 22504687
   PubMedGoogle Scholar